RCC Market Snapshot: In A Crowded Field, What's Next?
• By The Pink Sheet
Just five years ago, the treatment options for patients with advanced kidney cancer were limited, but today, the market for renal cell carcinoma drugs is one of the most crowded in the oncology field, with six targeted agents on the market and more on the way
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
